Share
Angel S. Angelov
Vistagen, a late clinical-stage biopharmaceutical company focused on developing innovative intranasal therapies targeting nose-to-brain neurocircuitry, has appointed Angel S. Angelov, MD, MBA, as Chief Medical Officer (CMO).
Dr. Angelov brings extensive experience in clinical development, medical affairs, and neuroscience-focused therapeutics. Prior to joining Vistagen, he served as Chief Medical Officer at Theranica, a company specializing in neuromodulation therapies. His previous leadership roles include Managing Director at ANG Holding, Vice President and Head of Medical Affairs at Karuna Therapeutics, and Vice President, Clinical Leader for the VMAT-2 Franchise and Head of Medical Affairs at Neurocrine Biosciences.
Throughout his career, Dr. Angelov has also held clinical development and medical affairs positions at CollaGenex, Indivior, Novartis, NuPathe, and Teva. In addition, he has served in academic roles at Thomas Jefferson University and Temple University, contributing to both clinical practice and medical education.
Dr. Angelov earned his medical degree from Sofia Medical University and completed his residency and fellowship training at Thomas Jefferson University. He also holds an MBA from the Wharton School of the University of Pennsylvania. Board-certified in Psychiatry, he is a diplomate of the American Board of Psychiatry and Neurology and maintains an active medical license in Pennsylvania.
As Chief Medical Officer, Dr. Angelov will support Vistagen’s clinical development programs and help advance the company’s pipeline of pherine-based therapeutic candidates designed to address neuroscience-related disorders.
In connection with his appointment, Vistagen’s Board of Directors granted Dr. Angelov an inducement stock option to purchase up to 150,000 shares of the company’s common stock under Nasdaq Listing Rule 5635(c)(4). The option carries an exercise price of $0.5955 per share and follows a vesting schedule that includes 25% vesting after one year, with the remaining shares vesting monthly over the subsequent 36 months.
